Rights issue

  • 09:28

Immunicum announces fully underwritten rights issue of about SEK 111 million to extend phase II-trial with new clinics in the US and to initiate clinical trials in melanoma in the US and in Sweden.

Read the press release here: Press release 160425 – Rights issue